%0 Journal Article
%T Antitumor activity of pluripotent cell-engineered vaccines and their potential to treat lung cancer in relation to different levels of irradiation
%A Ai-ling Wu
%A Dong-ming Wu
%A Huan-Huan Yang
%A Wen-hui Zhang
%A Xian-cheng Chen
%A Xiao-gang Duan
%A Yan-na Zhang
%A Yu-Quan Wei
%J Archive of "OncoTargets and therapy".
%D 2016
%R 10.2147/OTT.S97587
%X Cancer stem cells (CSCs) are critical for tumor initiation/maintenance and recurrence or metastasis, so they may serve as a potential therapeutic target. However, CSC-established multitherapy resistance and immune tolerance render tumors resistant to current tumor-targeted strategies. To address this, renewable multiepitope-integrated spheroids based on placenta-derived mesenchymal stem cells (pMSCs) were X-ray-modified, at four different irradiation levels, including 80, 160, 240, and 320 Gy, as pluripotent biologics, to inoculate hosts bearing Lewis lung carcinoma (LL2) and compared with X-ray-modified common LL2 cells as control. We show that the vaccines at the 160/240 Gy irradiation levels could rapidly trigger tumor cells into the apoptosis loop and evidently prolong the tumor-bearing host¡¯s survival cycle, in contrast to vaccines irradiated at other levels (P<0.05), with tumor-sustaining stromal cell-derived factor-1/CXCR4 pathway being selectively blockaded. Meanwhile, almost no or minimal toxicity was detected in the vaccinated hosts. Importantly, 160/240 Gy-irradiated vaccines could provoke significantly higher killing of CSCs and non-CSCs, which may provide an access to developing a novel biotherapy against lung carcinoma
%K lung carcinoma
%K placenta-derived mesenchymal stem cells (pMSCs)
%K attenuated vaccine
%K irradiation level
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795574/